Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Public ClinicalTrials.gov record NCT03267940. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).
Study identification
- NCT ID
- NCT03267940
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 85 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2, 2017 (Actual)
- Primary completion
- Nov 11, 2019 (Actual)
- Completion
- Nov 11, 2019 (Actual)
- Last update posted
- Feb 7, 2020
2017 – 2019
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic of Arizona | Phoenix | Arizona | 85054 | — |
| University of Arizona | Tucson | Arizona | 85724 | — |
| City of Hope | Duarte | California | 91010 | — |
| Scripps | La Jolla | California | 92037 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of California Irvine Division of Hematology-Oncology, Department of Medicine UC Irvine Health | Orange | California | 92868 | — |
| UC Davis | Sacramento | California | 95817 | — |
| UCLA - David Geffen School of Medicine | Santa Monica | California | 90404 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90603 | — |
| Yale Cancer Center | New Haven | Connecticut | 06511 | — |
| Lombardi Cancer Center, Georgetown University | Washington D.C. | District of Columbia | 20007 | — |
| Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Mount Sinai | New York | New York | 10029 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15232 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| UT Health Cancer Center | San Antonio | Texas | 78229 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
| Virginia Mason | Seattle | Washington | 98101 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Froedtert Hospital And Medical College | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03267940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 7, 2020 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03267940 live on ClinicalTrials.gov.